a b s t r a c t
This data article contains a supplementary figure and validation data relating to the research article entitled "Genotyping of wildtype cytochrome P450 2A6 and whole-gene deletion using human blood samples and a multiplex real-time polymerase chain reaction method with dual-labeled probes" (Shimizu et al., Clinica Chimica Acta 441, 71-74, 2015), which presents a multiplex realtime polymerase chain reaction method with dual-labeled probes for human P450 2A6 wild-type and whole-gene deletion. Real-time methods have dramatically improved the speed of complex genetic diagnostics compared to conventional assays based on restriction enzyme digestion. Here, we show the basic assay validation data by single and multiplex determinations in comparison with commercial TaqMan copy number assays for P450 2A6.
& Value of the data 1. A real-time polymerase chain reaction (PCR) assay for cytochrome P450 2A6 genotyping recently developed [1] was fully validated using a conventional PCR-restriction fragment length polymorphism (RFLP) method ( Fig. 1 ). 2. Aside from the PCR-based methods outlined in this report, commercially available TaqMan assays for copy number determinations (whole-gene deletion P450 2A6*4 genotyping in regions of limited homology) were almost validated (Table 1 ). 3. Genotyping strategies for P450 2A6 wild-type (P450 2A6*1) and whole-gene deletion (P450 2A6*4) alleles defined here could be combined with highly automated genome-wide association studies, which have limited utility for identifying whole-gene deletions. 4. The dataset that supports the genotyping validations of human P450 2A6 wild-type and whole gene deletion are provided by single and multiplex determinations in comparison with commercial TaqMan copy number assays.
Data
Validation of genotyping of human wild-type P450 2A6*1 and whole-gene deletion P450 2A6*4 by both PCR-RFLP and real-time platforms was carried out. One of the 45 subjects (genotyped as P450 P450 2A6 genotype 2A6*1B/*1B, Table 1 ) was not matched in term of P450 2A6 copy numbers (around 1) in the current TaqMan analysis.
Experimental design, materials and methods
The ethics committee of Showa Pharmaceutical University approved this analysis in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki). Informed consent was obtained for experimentation from all subjects. Genotyping of P450 2A6 (P450 2A6*1A, 2A6*1B, and 2A6*4) was carried out by conventional PCR amplification (Fig. 1) as described previously [2] [3] [4] . Blood samples were obtained with puncture needles, lysed, and stabilized [5] . Blood samples from healthy non-smoking Japanese volunteers or DNA fractions extracted separately by the standard protocol from the volunteers' buccal cells were used for real-time detection of P450 2A6 wild-type and whole-gene deletion [1] . The samples also underwent TaqMan Copy Number Assays (Hs07545274, Hs04488984, and Hs07545275; ThermoFisher Scientific, Waltham, MA, USA). The P450 2A6 copy numbers in the human genomes were calculated using CopyCaller software according to the manufacturer's instructions with designed human RNase P TaqMan Copy Number Reference Assays (4403326; ThermoFisher Scientific) after duplex real-time PCR reactions.
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